Today, MJFF Board member Ryan Reynolds opens up on the cover of PEOPLE Magazine | PEOPLE.com and sheds light on his family’s journey with Parkinson’s disease. Ryan and his mother Tammy, part of the educational #MoretoParkinsons campaign, provide a candid conversation as loved ones caring for their father and husband James (Jim) Reynolds who lived with Parkinson’s disease and experienced hallucinations and delusions. Ryan shares, “At the time I just thought, ‘My dad’s losing his mind.’ My father was really slipping down a rabbit hole where he was struggling to differentiate between reality and fiction.” Not everyone with Parkinson’s disease experiences hallucinations or delusions. Like all Parkinson’s symptoms, if, when and to what degree they occur varies from person to person. But it’s normal and perfectly understandable to worry about the possibility of these symptoms. Learn more about what these symptoms can look like, how to talk about hallucinations and delusions with loved ones and doctors and what medication and non-medication strategies may help you and your care partners ease these symptoms. https://bit.ly/3X4LqLx
The Michael J. Fox Foundation for Parkinson's Research
Research Services
New York, NY 41,076 followers
Here. Until Parkinson's isn't.
About us
The Michael J. Fox Foundation for Parkinson's Research is dedicated to finding a cure for Parkinson's disease through an aggressively funded research agenda and to ensuring the development of improved therapies for those living with Parkinson's today.
- Website
-
http://www.michaeljfox.org
External link for The Michael J. Fox Foundation for Parkinson's Research
- Industry
- Research Services
- Company size
- 51-200 employees
- Headquarters
- New York, NY
- Type
- Nonprofit
- Founded
- 2000
Locations
-
Primary
Grand Central Station
P.O. Box 4777
New York, NY 10163-4777, US
Employees at The Michael J. Fox Foundation for Parkinson's Research
-
Cynthia Ramnarace
Editorial Content Strategy
-
Susan Otten, MBA, ABC
Logistics, marketing, engineering services for CPG & shelf stable food businesses who do good. Appalachian Trail Thru-Hiker for Parkinson's Disease…
-
Kevin Murray
Fundraiser, Trial Participant, Motorsports Enthusiast
-
Ted Thompson
Senior VP @ MJFF | Leading Parkinson's Public Policy
Updates
-
Deadline Approaching: Neurology residents are invited to join us in Chicago this fall for a free, expert-led course on research, care and careers in movement disorders. Apply by September 6th. bit.ly/4eixDav.
-
Evidence supports that dysfunction in the homeostasis of iron and other elements likely contributes to the pathophysiological mechanisms of Parkinson's disease, but we have yet to develop suitable elemental biomarkers for use in diagnosing and monitoring the progression of Parkinson's disease. In the latest episode of the Parkinson’s Research Podcast, Dr. Paul Lingor, Professor of Neurology at the Technical University of Munich, discusses his work to identify patterns of bioelements in CSF that could serve as PD biomarkers. Beyond CSF, he is also examining tear fluid as a potential biomarker source that is easier to collect. Listen to the episode now: https://bit.ly/4dC1REl *This podcast is geared toward researchers and clinicians. If you live with Parkinson’s or have a friend or family member with PD, listen to The Michael J. Fox Foundation Parkinson’s Podcast. Hear from scientists, doctors and people with Parkinson's on different aspects of life with the disease as well as research toward treatment breakthroughs at https://lnkd.in/eAp9HDGe.
Episode 20: Studying CSF Element Profiles and Tear Fluid as Potential Biomarkers, and Novel and Combined Therapies for PD with Paul Lingor
michaeljfox.org
-
The U.S. Food and Drug Administration (FDA) has approved a new, long-acting oral formulation for the treatment of Parkinson’s disease (PD). Developed by Amneal Pharmaceuticals, Crexont is an extended-release formulation of levodopa/carbidopa that aims to alleviate symptoms longer with fewer doses and offer patients improved symptom control and a better quality of life. Read more about this treatment and the bustling pipeline of PD drugs: https://bit.ly/3yxZKTm
-
As an early career movement disorder clinician-researcher, Dr. Francesca Magrinelli has provided care to hundreds of patients, conducted research on the genetics of early-onset Parkinson’s disease and carried out genetic testing in low-income communities. Dr. Magrinelli is one of 40 movement disorder specialists to graduate from the Edmond J. Safra Fellowship in Movement Disorders to date and credits the program for laying the foundation for her career. This fellowship annually funds academic centers worldwide to identify and train a new movement disorder clinician-researcher over a two-year period. Applications for the next funding cycle are now open. Learn more and apply: bit.ly/3WDekke
-
Last week, Representative Jennifer Wexton and Gus Bilirakis introduced the HEALTHY BRAINS Act, a new bill that would direct the federal government to research the link between environmental risk factors, like exposure to toxic chemicals, and neurodegenerative diseases including Parkinson’s. Millions of Americans, including those living with Parkinson’s and their families, stand to benefit from a concerted federal effort to better understand and identify the effects of dangerous and harmful environmental risks. Representatives Wexton and Bilirakis were both instrumental in getting the National Plan to End Parkinson’s Act across the finish line, and we’re so grateful to them for continuing to champion the Parkinson’s community in Congress with this new bill! Take a minute to urge your representatives to support the HEALTHY BRAINS Act: https://bit.ly/3YuXjLK Photo Credit: Brian Thorpe
-
Thank you to NeuroDerm, A Mitsubishi Tanabe Pharma Group Company for sponsoring this year’s Parkinson’s Disease Therapeutics conference. MT Pharma America & NeuroDerm are recreating a future for Parkinson’s by driving healthcare innovation and patient-centric solutions through Pharma & MedTech integration. The PD Therapeutics Conference is The Michael J. Fox Foundation's annual scientific conference and the only one in the world focused exclusively on Parkinson's disease drug development. Our 16th annual conference will be happening on October 17th in New York City. Visit our website to learn more. https://bit.ly/3yr9gra
2024 Parkinson's Disease Therapeutics Conference
michaeljfox.org
-
“If you put the right people around you” — in a boat or not — “you can pretty much achieve anything.” This morning, Team Human Powered Potential’s inspiring 2,800 mile journey was featured on CNN after speaking with reporter Sandra Gonzalez. They reflected on their arduous journey across the Pacific Ocean and how their athletic feat has catapulted an unprecedented fundraising effort raising over $28 million for Parkinson’s disease research. https://cnn.it/46wQLyc Team HPP was one of nine teams participating in The World's Toughest Row. Patrick Morrissey, diagnosed with Parkinson’s in 2019, alongside his friends and fellow rowers Brendan Cusick, Peter Durso and Scott Forman, made history in three epic ways: Setting a race record by raising more than any other World’s Toughest Row individual team since its inception with $10,000 for each mile rowed, becoming the first four-man American team to complete the Pacific crossing and Morrissey also becomes the first person with PD to row across the Pacific. With the original milestone completed and thanks to the generosity of an anonymous donor, all contributions to the team’s journey and the Foundation’s mission have extended the match to target a $41 million goal in honor of the team’s 41 days at sea. Donate now to the extended match: https://bit.ly/3YuaHjp
-
It’s often believed that Parkinson’s is an “old white man’s disease.” However, the more we learn about Parkinson's, the more we understand the diversity of people it affects. In this clip from one of our podcast episodes, MJFF Patient Council member, Soania Mathur leads a discussion with panelists: • Richelle Flanagan, Parkinson’s advocate, registered dietician and co-founder of the Women's Parkinson's Project. • Omotola Thomas, founder and director of Parkinson's Africa, diagnosed with PD in 2016. • Kat Hill, MSN, author, speaker, advocate and co-founder of the Women's Parkinson's Project, diagnosed with PD in 2015. Together, they discuss the challenges faced by women due to delayed diagnosis, hormonal changes, lack of information and treatment, inequity in research and gender biases. They share with listeners how they empower themselves to live better with the disease by advocating for themselves with their health care team and how they empower other women through awareness and activism. Listen now: https://bit.ly/4frqo0M
-
With several new drugs for Parkinson’s disease currently in the pipeline, you might be curious about what exactly goes into getting a new drug approved by the U.S. Food and Drug Administration (FDA). In our latest blog, we break down the approval process for new drugs, including applications, cost, timelines and what each phase of drug testing entails. Learn more: https://bit.ly/4f7ph66
What Does it Take to Get a Parkinson's Drug Approved by the FDA?
michaeljfox.org